Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Financial Post ·
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2 HLP004 Program progressing with Phase 2 monotherapy study for the potential treatment of generalized anxiety disorder (“GAD”) expected to initiate in Q1 20271,,2,3 This news release constitutes a […]
Notes Read More